Basit öğe kaydını göster

dc.contributor.authorAltintas, Ebru
dc.date.accessioned2019-09-30T11:55:42Z
dc.date.available2019-09-30T11:55:42Z
dc.date.issued2015
dc.identifier.issn1018-8681
dc.identifier.urihttp://www.dusunenadamdergisi.org/ing/DergiPdf/DUSUNEN_ADAM_DERGISI_37e5d02b085e4ced9cf49877da99c0de.pdf
dc.identifier.urihttp://hdl.handle.net/11727/4021
dc.description.abstractChloroquine and its derivative hydroxychloroquine (HCQ) have been used for acute and prophilactic treatment of malaria for most of the last century. HCQ has anti-inflammatory, antilipidemic and antithrombotic effects and in recent years has become an important drug for treating rheumatoid arthritis ( RA). In the literature, antimalarial-induced psychosis has been reported in a small number of cases; however, we did not find any case related with HCQ-induced psychosis in rheumatoid arthritis. We want to report a 73-year-old female RA patient without a previous history of psychosis who developed psychosis after use of HCQ. HCQ is being increasingly prescribed in autoimmune diseases. Clinicians need to be aware of psychosis as a rare but debilitating side effect.en_US
dc.language.isoengen_US
dc.relation.isversionof10.5350/DAJPN2015280409en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHydroxychloroquineen_US
dc.subjectpsychosisen_US
dc.subjectside-effecten_US
dc.titleHydroxychloraquine-Induced Acute Psychotic Disorder in a Female Patient with Rheumatoid Arthritis: a Case Reporten_US
dc.typearticleen_US
dc.relation.journalDUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCESen_US
dc.identifier.volume28en_US
dc.identifier.issue4en_US
dc.identifier.startpage369en_US
dc.identifier.endpage373en_US
dc.identifier.wos000421442700010en_US
dc.identifier.scopus2-s2.0-84953714394en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster